ClinicalTrials.gg
CompletedNCT03117270TORTUGAUpdated Aug 13, 2018

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

A Phase 2 interventional study of filgotinib and Placebo Oral Tablet in Ankylosing Spondylitis, sponsored by Galapagos NV. Completed at 30 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-13.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Spondylitis, Ankylosing with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · Ukraine.

Enrollment
8th of 10
116 · median 263
Started
2017
with 1 other
Phase 2
4 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
2 of 11
Galapagos NV

Among the 11 studies in Spondylitis, Ankylosing with a site in Ukraine, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 7th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

None of the 11 studies in Spondylitis, Ankylosing with a site in Ukraine is open now. The open studies under Spondylitis, Ankylosing, anywhere →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spondylitis, Ankylosing with a site in Ukraine as a file.
02

Study summary

This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with active Ankylosing Spondylitis (AS). A total of approximately 100 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo q.d. Treatment duration will be 12 weeks. Each subject will stay in the study for a maximum of 20 weeks (from Screening visit to Follow-up visit).

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects who are ≥18 years of age on the day of signing .
  • Diagnosis of moderate to severe ankylosing spondylitis with documented evidence of fulfilling the Modified New York (NY) criteria
  • Have active ankylosing spondylitis with a BASDAI ≥4 (numeric rating scale [NRS] 0-10) and spinal pain ≥4 (0-10 NRS) (based on BASDAI question 2, see protocol) at screening and baseline.
  • Have had a documented inadequate response to NSAIDs including cyclooxygenase-2 (COX-2) inhibitors.
  • If using cDMARD therapy, stable dose for at lead 4 weeks prior to Baseline.
  • If using non-drug therapies (including physical therapies), these should be kept stable during screening.
  • Male and female subjects of who engage in heterosexual intercourse must agree to use highly effective methods of as described in the protocol.

Key Exclusion Criteria:

  • Use of JAK inhibitors, or approved, at any time, including filgotinib;
  • Prior use of more than one TNF inhibitor, at any time.
  • Use of oral at a dose >10 mg/day of prednisone or prednisone equivalent or at a dose that hasn't been stable for at least 4 weeks prior to baseline;
  • Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4 weeks prior to screening;
  • Use of more than 1 NSAID or COX-2 inhibitor.
  • to MRI.
  • History of known or suspected complete ankylosis of the spine.
  • Presence of very poor functional status or unable to perform self-care.
  • Have undergone surgical treatment for ankylosing spondylitis within the last 12 weeks prior to screening.
  • Administration of a live or attenuated vaccine within 12 weeks prior to baseline.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    oral filgotinib tablets

    Drug: filgotinib

  • Placebo comparator
    placebo tablets

    Drug: Placebo Oral Tablet

Interventions

  • one filgotinib oral tablet q.d.

  • DrugPlacebo Oral Tablet

    one placebo oral tablet q.d.

06

What researchers measure

Primary outcomes

  1. Ankylosing Spondylitis disease activity score (ASDAS) in filgotinib treated subjects as compared to placebo

    To evaluate the effect of filgotinib on the AS disease activity score

    Time frame: week 12

Secondary outcomes

  1. Assessment of SpondyloArthritis international Society (ASAS) in filgotinib treated subjects as compared to placebo

    To evaluation the effect of filgotinib on the ASAS score in AS patients

    Time frame: week 12

  2. Assessment by a trained joint assessor of 44 joints for tenderness (counting the number or tender joints - TJC) and swelling (counting the number of swollen joints - SJC) in filgotinib treated subjects as compared to placebo

    To evaluate the effect of filgotinib on joint tenderness and swelling in AS patient

    Time frame: week 12

  3. Assessement of the Bath Ankylosing Spondylitis Disease Activity Index in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on BAS disease activity index in AS patients

    Time frame: week 12

  4. Assessment of the Bath Ankylosing Spondylitis Functional Index in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on BAS functional index in AS patients

    Time frame: week 12

  5. Assessment of the Bath Ankylosing Spondylitis Metrology Index in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on BAS metrology index in AS patients

    Time frame: week 12

  6. Assessment Spondyloarthritis Research Consortium of Canada MRI in filgotinib treated subjects as compared to placebo

    To assess the effect of filogtinib on Spondyloarthritis Research Consortium of Canada MRI in AS patients

    Time frame: week 12

  7. Assessment of the Maastricht Ankylosing Spondylitis Enthesitis Score in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinibe on Maastricht Ankylosing Spondylitis Enthesitis Score in AS patients

    Time frame: week 12

  8. Assessment of FACIT fatigue scale in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on FACIT fatigue scale in AS patients

    Time frame: week 12

  9. Assessment of SF-36 health survey in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on SF-36 health survey in AS patients

    Time frame: week 12

  10. Assessment of Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on ASQoL in AS patients

    Time frame: week 12

  11. Difference between filgotinib treated subjects and placebo subjects in the number of Adverse events

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: from baseline until the final follow up visit (week 16)

  12. Difference in the number of filgotinib subjects and placebo subjects with abnormal Clinical laboratory evaluations

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: from baseline until the final follow up visit (week 16)

  13. Difference in the number of filgotinib treated subjects and placebo subjects with abnormal vital signs

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: from baseline until the final follow up visit (week 16)

  14. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal physical examination

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: from baseline until the final follow up visit (week 16)

  15. Difference between the number of filgotinib treated subjects and placebo with abnormal ECG

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: At baseline, end of study visit (week 12) and final follow up visit (week 16)

  16. Difference between the number of filgotinib treated subjects and placebo with abnormal radiographic assessment

    To assess safety and tolerability of filgotinib in AS patients

    Time frame: At baseline and end of study visit (week 12)

07

Study locations

30 sites
  • ULB Hopital Erasme, Service de Rheumatology
    Brussels, Belgium
  • Eurohospital
    Plovdiv, Bulgaria
  • UMHAT Kaspela EOOD
    Plovdiv, Bulgaria
  • Medical Center "Teodora", EOOD
    Ruse, Bulgaria
  • Akademik Ivan Geshov, UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
  • Clinic of Rheumatology, UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
  • UMHAT "SofiaMed", OOD, Block 1
    Sofia, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, Bulgaria
  • Revmatologicka ambulance
    Ostrava, Czechia
  • CCBR Czech, a.s
    Pardubice, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, Czechia
  • OÜ Innomedica
    Tallinn, Estonia
  • Centrum Medyczne SILESIANA Sp z oo
    Bytom, Poland
  • Twoja Przychodnia-Centrum Medyczne Nowa Sol
    Nowa Sól, Poland
  • Ai Centrum Medyczne sp. z o.o. sp.k.
    Poznań, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z, Przychodnia Specjalistyczna
    Toruń, Poland
  • Centrum Medyczne AMED, Warszawa Targowek
    Warsaw, Poland
  • Corporacio Sanitaria Parc Tauli, Servicio de Reumatologia
    Santiago de Compostela, Spain
  • Hospital Infanta Luisa, Servicio de Reumatologia
    Sevilla, Spain
  • Hospital Universitario Virgen Macarena, Dept. of Rheumatology
    Sevilla, Spain
  • CI of Healthcare Kharkiv CCH #8 Dept of Rheumatology Kharkiv MA of PGE of MOHU, Ch of Cardiology and Funct Diagnostics
    Kharkiv, Ukraine
  • CNI Consultative and Diagnostic Center of Pecherskyi District of Kyiv, Department of Therapy
    Kiev, Ukraine
  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU, Unit of Non-coronary HD&Rh
    Kiev, Ukraine
  • CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU, Ch of Family Medicine & Dermatology, Venereology
    L'viv, Ukraine
  • M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA, Ch of Family Medicine and Therapy
    Poltava, Ukraine
  • CI of TRC
    Ternopil', Ukraine
  • A.Novak Transcarpathian Regional Clinical Hospital, Dept of Rheumatology
    Uzhgorod, Ukraine
  • M.I. Pyrogov VRCH Dept of Rheumatology M.I. Pyrogov VNMU, Ch of IM #1
    Vinnytsia, Ukraine
  • SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Un of Therapy and CRh Dept of Therapy
    Vinnytsia, Ukraine
  • MCIC MC LLC Health Clinic, Unit of Cardiology and Rheumatology
    Vinnytsya, Ukraine
08

References and documents

Publications

  • Maksymowych WP, Ostergaard M, Landewe R, Barchuk W, Liu K, Gilles L, Hendrikx T, Besuyen R, Baraliakos X. Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Rheumatology (Oxford). 2022 May 30;61(6):2388-2397. doi: 10.1093/rheumatology/keab758. PubMed 34647992 ↗
  • Maksymowych WP, Ostergaard M, Landewe R, Barchuk W, Liu K, Tasset C, Gilles L, Hendrikx T, Besuyen R, Baraliakos X. Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). Rheumatology (Oxford). 2022 May 5;61(5):2063-2071. doi: 10.1093/rheumatology/keab543. PubMed 34352069 ↗
  • van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewe R. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22. PubMed 30360970 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jul 2018, 15 months.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 15 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2017
First posted
Apr 17, 2017
StartActual
Mar 7, 2017
Primary completionActual
Jul 2, 2018
CompletionActual
Jul 2, 2018
Last update
Aug 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03117270
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Apr 17, 2017
Start date
Mar 7, 2017
Primary completion
Jul 2, 2018
Completion
Jul 2, 2018
Last update
Aug 13, 2018

Study contacts

Pille Harrison, MD, DPhil, MRCP (UK)
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion